Eisai
Manufacturing · Japan · 11,067 Employees
View Company Info for Free
About
Headquarters
4-6-10 Koishikawa Bunkyo-ku, Tokyo, Tokyo, 112-...Phone Number
+81 338173700Website
www.eisai.comRevenue
$5.1 BillionStock Symbol
ESAIYIndustry
Most Recent Scoops
Who is Eisai
Eisai Org Chart
Is Eisai your ideal customer?
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Eisai launches new products
Funding: Get notified immidiatlly once Eisai has new funding data
Congratulate Masked Content for being promoted to Masked Content at Eisai
Eisai, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Eisai recently announced quarterly report
Website visits: Recent activity has been detected on your website
Check out if Eisai is spiking on competitors!
Check if Eisai has recently received funding, and reach out quickly before it becomes old news!
Click to see if Eisai had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Eisai
Compare insights from companies similar to Eisai, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Eisai Email Formats
Eisai uses at least 5 email formats with first_last (ex. John_Smith@eisai.com) being used 49.3% of the time
Eisai Email Formats | Percentage | |
---|---|---|
first_last | John_Smith@eisai.com | 49.3% |
first.last | John.Smith@eisai.com | |
first + last | JohnSmith@eisai.com | |
first | John@eisai.com | |
last | Smith@eisai.com |
Get Verified Emails
Eisai Employee Growth Rate
Percentage of growth
1st year Mask
2nd year Mask
Eisai Tech Stack
A closer look at the technologies used by Eisai
Most Recent Scoops
Eisai News & Media
"LEQEMBI®" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico
TOKYO and CAMBRIDGE, Mass., Dec. 4, 2024 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the Federal Commission..."LEQEMBI®" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea
TOKYO and CAMBRIDGE, Mass., Nov. 27, 2024 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the humanized...Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the "AD-DMT Registry" in Japan
TOKYO, Nov 26, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Japan Ltd. announced today that Eisai has entered into a research collaboration agreement with the National Center of Neurology and Psychiatry to conduct apolipoprotein E (APOE) genetic testing in the dementia research and development program, “Development and Analysis of a National Clinical Registry of Disease-Modifying Therapies for Alzheimer’s Disease” (“AD-DMT Registry”). The research will be implemented by the Japan Agency foRozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan
TOKYO, Nov 20, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that the amyotrophic lateral sclerosis (ALS) treatment “Rozebalamin® for Injection25 mg” (mecobalamin) has been launched in Japan as a treatment for slowing progression of functionalimpairment in amyotrophic lateral sclerosis. The product received manufacturing and marketing approval in Japan on September 24, 2024, and was published in Japan’s National Health Insurance Drug Price List today. This approval is based on the resu
Frequently Asked Questions Regarding Eisai
Eisai is a company that focuses not only on developing pharmaceuticals but also the potential of corporative activities that go beyond the provision of medicines. We believe that our mission is not limited to simply delivering the drugs to the patient. All Eisai employees give first thought to patients and the people in the daily living domain, and... Read More